

# Recurrent activating ACVR1 mutations in diffuse intrinsic

Nature Genetics

46, 457-461

DOI: [10.1038/ng.2925](https://doi.org/10.1038/ng.2925)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. <i>CNS Oncology</i> , 2014, 3, 421-431.	1.2	21
2	Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 134.	2.4	27
3	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2014, 128, 733-741.	3.9	116
4	Molecular characteristics of pediatric high-grade gliomas. <i>CNS Oncology</i> , 2014, 3, 433-443.	1.2	26
5	ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. <i>Nature Genetics</i> , 2014, 46, 421-422.	9.4	20
6	O8.04 * TEMOZOLOMIDE AFTER RADIOTHERAPY IN RECURRENT "LOW-GRADE" DIFFUSE BRAINSTEM GLIOMA IN ADULTS. <i>Neuro-Oncology</i> , 2014, 16, ii18-ii18.	0.6	0
7	Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. <i>Pharmacogenomics</i> , 2014, 15, 1639-1641.	0.6	4
8	ACVR1 mutationsâ€”a key piece in paediatric diffuse glioma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 300-300.	12.5	4
9	Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5630-5640.	3.2	124
10	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. <i>Acta Neuropathologica</i> , 2014, 128, 615-627.	3.9	49
11	A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. <i>Acta Neuropathologica</i> , 2014, 128, 743-753.	3.9	114
12	Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 59.	2.4	35
14	Temozolomide after radiotherapy in recurrent â€œlow gradeâ€•diffuse brainstem glioma in adults. <i>Journal of Neuro-Oncology</i> , 2014, 120, 581-586.	1.4	17
15	The Genetic Signatures of Pediatric High-Grade Glioma: No Longer a One-Act Play. <i>Seminars in Radiation Oncology</i> , 2014, 24, 240-247.	1.0	43
16	Histone H3 Variants and Their Chaperones During Development and Disease: Contributing to Epigenetic Control. <i>Annual Review of Cell and Developmental Biology</i> , 2014, 30, 615-646.	4.0	107
17	<i>ACVR1</i> Mutations in DIPG: Lessons Learned from FOP. <i>Cancer Research</i> , 2014, 74, 4565-4570.	0.4	76
18	Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. <i>Nature Reviews Cancer</i> , 2014, 14, 651-661.	12.8	241
19	Structureâ€”Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7900-7915.	2.9	84

#	ARTICLE	IF	CITATIONS
20	Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review. <i>Brain Tumor Pathology</i> , 2014, 31, 229-233.	1.1	21
21	PM-12 * Pax3 EXPRESSION ENHANCES PDGF-B-INDUCED BRAINSTEM GLIOMAGENESIS AND CHARACTERIZES A SUBSET OF BRAINSTEM GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v171-v171.	0.6	0
22	Pediatric gliomas as neurodevelopmental disorders. <i>Glia</i> , 2016, 64, 879-895.	2.5	51
23	New insights into central nervous system involvement in FOP: Case report and review of the literature. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2817-2821.	0.7	12
24	The historical change of brainstem glioma diagnosis and treatment: from imaging to molecular pathology and then molecular imaging. <i>Chinese Neurosurgical Journal</i> , 2015, 1, .	0.3	4
25	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2015, 5, 147.	1.3	91
26	Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. <i>Frontiers in Oncology</i> , 2015, 5, 148.	1.3	50
27	Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2015, 5, 172.	1.3	36
28	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <i>Lancet Oncology, The</i> , 2015, 16, e293-e302.	5.1	72
29	Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 889-900.	0.9	54
30	Cancer genomics: why rare is valuable. <i>Journal of Molecular Medicine</i> , 2015, 93, 369-381.	1.7	8
31	Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 786-809.	0.8	102
32	Chromatin signatures of cancer. <i>Genes and Development</i> , 2015, 29, 238-249.	2.7	171
33	Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2015, 17, 953-964.	0.6	56
34	Molecular Biology of Pediatric Brain Tumors and Impact on Novel Therapies. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 10.	2.0	6
35	Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors. <i>Current Oncology Reports</i> , 2015, 17, 436.	1.8	49
36	A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. <i>Angiogenesis</i> , 2015, 18, 209-217.	3.7	53
37	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	3.9	277

#	ARTICLE	IF	CITATIONS
38	Histone H3.3 and cancer: A potential reader connection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6814-6819.	3.3	25
39	Approaches Toward Improving the Prognosis of Pediatric Patients With Glioma: Pursuing Mutant Drug Targets With Emerging Small Molecules. Seminars in Pediatric Neurology, 2015, 22, 28-34.	1.0	11
40	Histone H3 mutations—a special role for H3.3 in tumorigenesis?. Chromosoma, 2015, 124, 177-189.	1.0	77
41	The Emerging Molecular Foundations of Pediatric Brain Tumors. Journal of Child Neurology, 2015, 30, 1838-1850.	0.7	17
42	Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genetics, 2015, 208, 367-373.	0.2	35
43	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	15.2	473
44	Transforming growth factor $\beta^2$ and bone morphogenetic protein actions in brain tumors. FEBS Letters, 2015, 589, 1588-1597.	1.3	32
45	Translating genomic discoveries to the clinic in pediatric oncology. Current Opinion in Pediatrics, 2015, 27, 34-43.	1.0	29
46	Targeted approaches to childhood cancer: progress in drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 483-495.	2.5	3
47	Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathologica, 2015, 130, 815-827.	3.9	482
48	Matters of context guide future research in TGF $\beta^2$ superfamily signaling. Science Signaling, 2015, 8, re10.	1.6	44
49	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular Cancer Therapeutics, 2015, 14, 2560-2568.	1.9	55
50	Surgical approaches for brainstem tumors in pediatric patients. Child's Nervous System, 2015, 31, 1815-1840.	0.6	80
51	Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Child's Nervous System, 2015, 31, 1773-1780.	0.6	145
52	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. Journal of Clinical Oncology, 2015, 33, 2986-2998.	0.8	175
53	Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy. Seminars in Pediatric Neurology, 2015, 22, 14-22.	1.0	12
54	Time to rethink the unthinkable: Upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Pediatric Blood and Cancer, 2015, 62, 3-4.	0.8	32
55	Diffuse Intrinsic Pontine Glioma: A Therapeutic Challenge. , 0, , .		0

#	ARTICLE	IF	CITATIONS
56	HG-76SPATIAL AND TEMPORAL HOMOGENEITY OF DRIVER MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, iii66.1-iii66.	0.6	0
57	Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. <i>Viruses</i> , 2016, 8, 138.	1.5	19
58	HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING "OLD STRATEGIES" WITH NEW APPROACHES. <i>Neuro-Oncology</i> , 2016, 18, iii55.4-iii56.	0.6	1
59	A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives. <i>Stem Cells International</i> , 2016, 2016, 1-15.	1.2	26
60	Brainstem Glioma in Adults. <i>Frontiers in Oncology</i> , 2016, 6, 180.	1.3	42
61	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1652-1665.	3.1	110
62	Advances in the biology and treatment of pediatric central nervous system tumors. <i>Current Opinion in Pediatrics</i> , 2016, 28, 34-39.	1.0	9
63	Diffuse Midline Gliomas with Histone $H3K27M$ Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. <i>Brain Pathology</i> , 2016, 26, 569-580.	2.1	334
64	Posterior Fossa Tumors. <i>Journal of Pediatric Neuroradiology</i> , 2016, 05, 089-110.	0.1	2
65	Novel asymptomatic CNS findings in patients with <i>ACVR1/ALK2</i> mutations causing fibrodysplasia ossificans progressiva. <i>Journal of Medical Genetics</i> , 2016, 53, 859-864.	1.5	12
66	TGF- $\beta$ 2 Superfamily Signaling. , 2016, , 37-50.		12
67	Mechanisms of action of bone morphogenetic proteins in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016, 27, 81-92.	3.2	78
68	Biopsy for diffuse intrinsic pontine glioma: a reappraisal. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 18, 390-391.	0.8	10
69	New Concepts in the Imaging of Pediatric Brain Tumors: The Revival of Age-old Real Estate Principles. <i>Current Radiology Reports</i> , 2016, 4, 1.	0.4	1
70	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 620-634.	1.2	42
71	Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. <i>Biochemical Society Transactions</i> , 2016, 44, 1117-1134.	1.6	40
72	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. <i>Neuro-Oncology</i> , 2016, 19, now181.	0.6	17
73	Bioinformatics analysis of the molecular mechanism of diffuse intrinsic pontine glioma. <i>Oncology Letters</i> , 2016, 12, 2524-2530.	0.8	23

#	ARTICLE	IF	CITATIONS
74	Signaling Receptors for TGF- $\beta$ Family Members. Cold Spring Harbor Perspectives in Biology, 2016, 8, a022053.	2.3	480
75	Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1115-1128.	2.4	13
76	Structural Basis of Intracellular TGF- $\beta$ Signaling: Receptors and Smads. Cold Spring Harbor Perspectives in Biology, 2016, 8, a022111.	2.3	65
77	Polo-like Kinase $\beta$ 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. BMC Cancer, 2016, 16, 647.	1.1	31
78	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	5.8	197
79	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Letters, 2016, 380, 10-19.	3.2	22
80	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	0.6	217
81	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of $^{89}\text{Zr}$ -Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	1.9	51
82	A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells. Neoplasia, 2016, 18, 60-70.	2.3	40
83	Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer, 2016, 62, 124-131.	1.3	58
84	Actions from head to toe: An update on Bone/Body Morphogenetic Proteins in health and disease. Cytokine and Growth Factor Reviews, 2016, 27, 1-11.	3.2	9
85	Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine and Growth Factor Reviews, 2016, 27, 93-104.	3.2	51
86	Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathologica Communications, 2016, 4, 1.	2.4	144
87	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 497-521.	9.6	37
88	Next-generation molecular diagnostics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 121-130.	1.0	1
89	Mutations in chromatin machinery and pediatric high-grade glioma. Science Advances, 2016, 2, e1501354.	4.7	69
90	Histone Variant H3.3: A versatile H3 variant in health and in disease. Science China Life Sciences, 2016, 59, 245-256.	2.3	6
91	Inactivating <i>MUTYH</i> germline mutations in pediatric patients with high-grade midline gliomas. Neuro-Oncology, 2016, 18, 752-753.	0.6	20

#	ARTICLE	IF	CITATIONS
93	ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-Driven Brainstem Glioma Model. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 819-829.	1.9	49
94	Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. <i>Acta Neuropathologica</i> , 2016, 131, 889-901.	3.9	70
95	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
96	An epigenetic gateway to brain tumor cell identity. <i>Nature Neuroscience</i> , 2016, 19, 10-19.	7.1	76
97	Diffuse Intrinsic Pontine Glioma. <i>Journal of Child Neurology</i> , 2016, 31, 1377-1385.	0.7	31
98	Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. <i>Journal of Neuro-Oncology</i> , 2016, 126, 27-36.	1.4	10
99	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	1.4	42
100	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 323-331.	1.4	27
101	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 19.	2.0	87
102	Therapeutic Potential for Bone Morphogenetic Protein 4 in Human Malignant Glioma. <i>Neoplasia</i> , 2017, 19, 261-270.	2.3	25
103	Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. <i>Neurotherapeutics</i> , 2017, 14, 274-283.	2.1	21
104	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. <i>Nature Medicine</i> , 2017, 23, 483-492.	15.2	392
105	Tissue sampling in diffuse intrinsic pontine glioma (DIPG) at progression. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26492.	0.8	0
106	Second re-irradiation for DIPG progression, re-considering "old strategies" with new approaches. <i>Child's Nervous System</i> , 2017, 33, 849-852.	0.6	14
107	Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. <i>Translational Oncology</i> , 2017, 10, 221-228.	1.7	48
108	H3-IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	3.9	144
109	Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 31, 635-652.e6.	7.7	290
110	BMP Signaling in Fibrodysplasia Ossificans Progressiva, a Rare Genetic Disorder of Heterotopic Ossification. , 2017, , 327-343.		0

#	ARTICLE	IF	CITATIONS
111	Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells. <i>Oncogene</i> , 2017, 36, 4963-4974.	2.6	30
112	Histone H3.3K27M Represses <i>p16</i> to Accelerate Gliomagenesis in a Murine Model of DIPG. <i>Molecular Cancer Research</i> , 2017, 15, 1243-1254.	1.5	120
113	Diffuse intrinsic pontine gliomas—current management and new biologic insights. Is there a glimmer of hope?. <i>Neuro-Oncology</i> , 2017, 19, 1025-1034.	0.6	91
114	A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. <i>Neurology</i> , 2017, 88, 1584-1589.	1.5	53
115	Characteristics of H3 K27M-mutant gliomas in adults. <i>Neuro-Oncology</i> , 2017, 19, 1127-1134.	0.6	207
116	Molecular mechanisms and therapeutic targets in pediatric brain tumors. <i>Science Signaling</i> , 2017, 10, .	1.6	53
118	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. <i>Experimental Cell Research</i> , 2017, 360, 397-403.	1.2	26
119	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	7.7	716
120	Distinct molecular profile of diffuse cerebellar gliomas. <i>Acta Neuropathologica</i> , 2017, 134, 941-956.	3.9	40
121	Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. <i>Npj Precision Oncology</i> , 2017, 1, 32.	2.3	17
122	Molecular mechanisms for activation of mutant activin receptor-like kinase 2 in fibrodysplasia ossificans progressiva. <i>Journal of Oral Biosciences</i> , 2017, 59, 121-126.	0.8	1
123	Molecular Basis of Pediatric Brain Tumors. <i>NeuroMolecular Medicine</i> , 2017, 19, 256-270.	1.8	13
124	Identification of novel ALK2 inhibitors and their effect on cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 121-127.	1.0	11
125	Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. <i>Npj Genomic Medicine</i> , 2017, 2, 29.	1.7	14
126	A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG). <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	33
127	Pediatric High Grade Glioma. <i>Current Cancer Research</i> , 2017, , 241-266.	0.2	1
129	Identification of complex genomic rearrangements in cancers using CouGaR. <i>Genome Research</i> , 2017, 27, 107-117.	2.4	31
130	Oncogenic Mechanisms of Histone H3 Mutations. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026443.	2.9	56



#	ARTICLE	IF	CITATIONS
131	Molecular pathology of paediatric central nervous system tumours. <i>Journal of Pathology</i> , 2017, 241, 159-172.	2.1	51
132	Oncohistones: drivers of pediatric cancers. <i>Genes and Development</i> , 2017, 31, 2313-2324.	2.7	85
133	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 2017, 8, 495.	1.6	48
134	Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma. <i>Frontiers in Oncology</i> , 2017, 7, 45.	1.3	45
135	Genomic Insights into Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2017, 7, 57.	1.3	59
136	Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. <i>PLoS ONE</i> , 2017, 12, e0169485.	1.1	130
137	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 331-342.	1.0	36
138	Polymodal allosteric regulation of Type 1 Serine/Threonine Kinase Receptors via a conserved electrostatic lock. <i>PLoS Computational Biology</i> , 2017, 13, e1005711.	1.5	16
139	Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. <i>Cell and Bioscience</i> , 2017, 7, 56.	2.1	40
140	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2017, 5, 78.	2.4	48
141	Epigenetics in Clinical Management of Children and Adolescents with Brain Tumors. <i>Current Cancer Drug Targets</i> , 2017, 18, 57-64.	0.8	13
142	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. <i>Journal of Clinical Oncology</i> , 2017, 35, 2370-2377.	0.8	223
143	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. <i>Journal of Clinical Oncology</i> , 2017, 35, 2346-2354.	0.8	25
144	Diffuse Intrinsic Pontine Glioma. , 2017, , 991-994.		0
145	Recent advances in understanding contextual TGF $\beta$ 2 signaling. <i>F1000Research</i> , 2017, 6, 749.	0.8	22
146	Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. <i>Nature Medicine</i> , 2018, 24, 572-579.	15.2	321
147	The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis. <i>Neurological Sciences</i> , 2018, 39, 1191-1201.	0.9	7
148	Reconstructing the molecular life history of gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 649-670.	3.9	61

#	ARTICLE	IF	CITATIONS
149	Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. <i>Oncogenesis</i> , 2018, 7, 13.	2.1	54
150	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	0.8	51
151	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018, 20, 1547-1555.	0.6	82
152	Histone H3 Mutations in Cancer. <i>Current Pharmacology Reports</i> , 2018, 4, 292-300.	1.5	44
153	H3 K27M mutant diffuse midline gliomas in different anatomical locations. <i>Human Pathology</i> , 2018, 78, 89-96.	1.1	98
154	Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders. <i>Bone</i> , 2018, 111, 101-108.	1.4	29
155	Gliomas in Children. <i>Seminars in Neurology</i> , 2018, 38, 121-130.	0.5	15
156	Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. <i>Brain Pathology</i> , 2018, 28, 103-111.	2.1	80
157	Bone Morphogenetic Protein-Based Therapeutic Approaches. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a022327.	2.3	53
158	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27
159	Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. <i>Bone</i> , 2018, 109, 104-110.	1.4	18
160	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
161	Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. <i>Bone</i> , 2018, 109, 251-258.	1.4	32
162	Signaling pathways and mesenchymal transition in pediatric high-grade glioma. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 871-887.	2.4	44
163	Histone Mutations in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 337-351.	2.3	23
164	Precision Medicine in Pediatric Neurooncology: A Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 11-28.	1.7	12
165	Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva. <i>Bone</i> , 2018, 109, 241-250.	1.4	33
166	Molecular alterations in pediatric brainstem gliomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26751.	0.8	12

#	ARTICLE	IF	CITATIONS
167	Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. <i>Bone</i> , 2018, 109, 91-100.	1.4	25
168	Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 343-351.	0.5	43
169	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. <i>Radiographics</i> , 2018, 38, 2102-2122.	1.4	75
170	Transcriptomic and epigenetic profiling of "diffuse midline gliomas, H3 K27M-mutant" discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. <i>Acta Neuropathologica Communications</i> , 2018, 6, 117.	2.4	83
171	Diffuse Intrinsic Pontine Glioma. , 0, , .		3
172	Epidemiology of Pediatric Central Nervous System Tumors. , 2018, , 1-15.		0
173	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
174	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221.		0
175	Unscheduled <sc>HDAC</sc>4 repressive activity in human fibroblasts triggers <sc>TP</sc>53-dependent senescence and favors cell transformation. <i>Molecular Oncology</i> , 2018, 12, 2165-2181.	2.1	19
176	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 85.	1.3	9
177	Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG). <i>Bioengineering</i> , 2018, 5, 88.	1.6	15
178	Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2018, 22, 678-683.	0.8	9
179	Population-based Study Determining Predictors of Cancer-Specific Mortality and Survival in Pediatric High-grade Brainstem Glioma. <i>World Neurosurgery</i> , 2018, 119, e1006-e1015.	0.7	14
180	Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva. <i>Methods in Molecular Biology</i> , 2018, 1828, 497-502.	0.4	3
181	Identification of small molecule inhibitors of ALK2: a virtual screening, density functional theory, and molecular dynamics simulations study. <i>Journal of Molecular Modeling</i> , 2018, 24, 262.	0.8	21
182	Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. <i>Journal of Controlled Release</i> , 2018, 281, 29-41.	4.8	99
183	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. <i>Nature Medicine</i> , 2018, 24, 1204-1215.	15.2	133
184	Alterations of Histone Modifications in Cancer. , 2018, , 141-217.		10

#	ARTICLE	IF	CITATIONS
185	Fibrodysplasia (Myositis) Ossificans Progressiva. , 2018, , 523-545.		2
186	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 5645-5657.	3.2	30
187	Pediatric Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 533-556.	0.8	163
188	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2018, 8, 127.	1.3	31
189	CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2018, 8, 191.	1.3	18
190	Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 51.	2.4	115
191	Brain cancer genomics and epigenomics. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 148, 785-797.	1.0	5
192	Mutant ATRX: uncovering a new therapeutic target for glioma. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 599-613.	1.5	103
193	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 290-295.	1.0	29
194	A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. <i>Oncogene</i> , 2019, 38, 6479-6490.	2.6	13
195	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
196	Signal Transduction in Diffuse Intrinsic Pontine Glioma. <i>Proteomics</i> , 2019, 19, 1800479.	1.3	36
197	ACVR1 Function in Health and Disease. <i>Cells</i> , 2019, 8, 1366.	1.8	47
198	The dark matter of diffuse intrinsic pontine gliomas: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 11-20.	0.5	1
199	PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. <i>Nature Communications</i> , 2019, 10, 3790.	5.8	54
200	Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. <i>Molecular Cell</i> , 2019, 76, 965-980.e12.	4.5	110
201	Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in <i>Drosophila melanogaster</i> . <i>Neuro-Oncology</i> , 2019, 21, 628-639.	0.6	5
202	Preclinical therapeutic targets in diffuse midline glioma. <i>Drug Resistance Updates</i> , 2019, 44, 15-25.	6.5	19

#	ARTICLE	IF	CITATIONS
203	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. <i>Communications Biology</i> , 2019, 2, 156.	2.0	73
204	Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 75.	2.4	24
205	Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer. <i>Cancers</i> , 2019, 11, 660.	1.7	105
206	Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. <i>EBioMedicine</i> , 2019, 43, 171-179.	2.7	23
207	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	1.3	51
208	Chemoproteomic Selectivity Profiling of PI3K and PI3K Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2019, 14, 655-664.	1.6	21
209	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2111-2123.	0.4	28
210	ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. <i>Nature Communications</i> , 2019, 10, 1023.	5.8	87
211	H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. <i>Nature Communications</i> , 2019, 10, 1262.	5.8	215
212	Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2019, 21, 786-799.	0.6	26
213	Developmental origins and oncogenic pathways in malignant brain tumors. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2019, 8, e342.	5.9	35
214	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. <i>Acta Neuropathologica</i> , 2019, 137, 637-655.	3.9	85
215	Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity. <i>Cancers</i> , 2019, 11, 1875.	1.7	14
216	Pediatric diffuse intrinsic pontine glioma: where do we stand?. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 759-770.	2.7	41
217	Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. <i>Current Opinion in Oncology</i> , 2019, 31, 522-530.	1.1	45
218	TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). <i>Clinical Cancer Research</i> , 2019, 25, 6788-6800.	3.2	66
219	Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma. <i>Trends in Cancer</i> , 2019, 5, 799-808.	3.8	13
220	Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. <i>Cancer Cell</i> , 2019, 35, 140-155.e7.	7.7	194

#	ARTICLE	IF	CITATIONS
221	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 253-263.	1.4	30
222	Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. <i>Acta Neuropathologica</i> , 2019, 137, 297-306.	3.9	109
223	High frequency of H3 K27M mutations in adult midline gliomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 839-850.	1.2	50
224	Bone morphogenetic protein receptor signal transduction in human disease. <i>Journal of Pathology</i> , 2019, 247, 9-20.	2.1	151
225	Genetics of Common Pediatric Brain Tumors. <i>Pediatric Neurology</i> , 2020, 104, 3-12.	1.0	14
226	Identification of prognostic markers in diffuse midline gliomas H3K27M mutant. <i>Brain Pathology</i> , 2020, 30, 179-190.	2.1	22
227	Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. <i>Neuro-Oncology</i> , 2020, 22, 195-206.	0.6	14
228	Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG). <i>Child's Nervous System</i> , 2020, 36, 697-704.	0.6	12
229	Pediatric intrinsic brainstem lesions: clinical, imaging, histological characterization, and predictors of survival. <i>Child's Nervous System</i> , 2020, 36, 933-939.	0.6	3
230	Investigating Protein-Protein Allosteric Network using Current-Flow Scheme. <i>Journal of Computational Chemistry</i> , 2020, 41, 552-560.	1.5	3
231	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. <i>Advances in Anatomic Pathology</i> , 2020, 27, 206-219.	2.4	7
232	Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 73-85.	1.8	22
233	Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas. <i>Cancers</i> , 2020, 12, 2813.	1.7	19
234	A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). <i>Journal of Neuro-Oncology</i> , 2020, 149, 511-522.	1.4	27
235	Pharmacokinetic Principles and Their Application to Central Nervous System Tumors. <i>Pharmaceutics</i> , 2020, 12, 948.	2.0	10
236	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
237	Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127418.	1.0	6
238	Oklahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma. <i>Journal of Translational Medicine</i> , 2020, 18, 424.	1.8	7

#	ARTICLE	IF	CITATIONS
239	Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10061-10085.	2.9	12
240	&lt;p&gt;miR-148a Regulates the Stem Cell-Like Side Populations Distribution by Affecting the Expression of ACVR1 in Esophageal Squamous Cell Carcinoma&lt;p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8079-8094.	1.0	12
241	Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. <i>Molecular Cancer Research</i> , 2020, 18, 1711-1723.	1.5	11
242	Fibrodysplasia Ossificans Progressiva: Report of two cases and review of the literature. <i>Oral and Maxillofacial Surgery Cases</i> , 2020, 6, 100198.	0.1	1
243	Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4978-4996.	2.9	15
244	Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas. <i>Scientific Reports</i> , 2020, 10, 8368.	1.6	48
245	Development of a human in vitro bloodâ€“brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 37.	2.4	27
246	Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors. <i>Bone</i> , 2020, 138, 115472.	1.4	65
247	The integrated genomic and epigenomic landscape of brainstem glioma. <i>Nature Communications</i> , 2020, 11, 3077.	5.8	50
248	ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 194-200.	0.6	9
249	Histone variant H3.3 residue S31 is essential for <i>Xenopus</i> gastrulation regardless of the deposition pathway. <i>Nature Communications</i> , 2020, 11, 1256.	5.8	38
250	Postâ€“mortem tissue donation programs as platforms to accelerate cancer research. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 163-170.	1.3	4
251	Invaders Exposed: Understanding and Targeting Tumor Cell Invasion in Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2020, 10, 92.	1.3	22
252	Job Opening for Nucleosome Mechanic: Flexibility Required. <i>Cells</i> , 2020, 9, 580.	1.8	5
253	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. <i>Cancer Cell</i> , 2020, 37, 308-323.e12.	7.7	56
254	Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene. <i>Bone</i> , 2020, 138, 115469.	1.4	4
255	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020, 10, 10954.	1.6	7
256	H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. <i>Acta Neuropathologica Communications</i> , 2020, 8, 8.	2.4	14



#	ARTICLE	IF	CITATIONS
257	Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application. <i>Cancers</i> , 2020, 12, 516.	1.7	14
258	Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. <i>Cancer Genetics</i> , 2020, 243, 19-47.	0.2	3
259	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. <i>Frontiers in Oncology</i> , 2019, 9, 1568.	1.3	18
260	Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2019, 9, 1436.	1.3	50
261	Characterization of the Blood–Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. <i>Pharmaceutics</i> , 2020, 12, 399.	2.0	18
262	Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 4080-4092.	3.2	18
263	Hypoxia Inducible Factors™ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches. <i>Cancers</i> , 2020, 12, 979.	1.7	15
264	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. <i>Molecular Cancer Research</i> , 2020, 18, 968-980.	1.5	18
265	Precise visual distinction of brain glioma from normal tissues via targeted photoacoustic and fluorescence navigation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 27, 102204.	1.7	10
266	Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible T <sub>1</sub> RI cross-talk in diffuse intrinsic pontine glioma. <i>Scientific Reports</i> , 2020, 10, 6140.	1.6	5
267	Histone Mutations and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, , .	0.8	3
268	Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?. <i>Neurological Sciences</i> , 2021, 42, 925-934.	0.9	10
269	Phosphatase magnesium-dependent 1 (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer. <i>Biochemical Pharmacology</i> , 2021, 184, 114362.	2.0	4
270	Diffuse intrinsic pontine glioma: current insights and future directions. <i>Chinese Neurosurgical Journal</i> , 2021, 7, 6.	0.3	35
271	Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges. <i>FEBS Journal</i> , 2022, 289, 1191-1213.	2.2	20
272	Genomic Heterogeneity of Aggressive Pediatric and Adult Diffuse Astrocytomas. <i>Molecular Pathology Library</i> , 2021, , 153-174.	0.1	0
273	Receptor-driven invasion profiles in diffuse intrinsic pontine glioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab039.	0.4	2
274	Symmetrical glial hyperplasia in the brainstem of fibrodysplasia ossificans progressiva. <i>Neuropathology</i> , 2021, 41, 146-151.	0.7	6



#	ARTICLE	IF	CITATIONS
275	MicroRNA bta-miR-365-3p inhibits proliferation but promotes differentiation of primary bovine myoblasts by targeting the activin A receptor type I. <i>Journal of Animal Science and Biotechnology</i> , 2021, 12, 16.	2.1	11
276	Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 540.	1.8	7
277	Molecular Stratification of Adult and Pediatric High Grade Gliomas. <i>Molecular Pathology Library</i> , 2021, , 123-151.	0.1	0
278	Brain stem gliomas and current landscape. <i>Journal of Neuro-Oncology</i> , 2021, 151, 21-28.	1.4	2
279	Molecular Characteristics of Thalamic Gliomas in Adults. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 1598-1604.	1.1	1
280	Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva. <i>Biomedicines</i> , 2021, 9, 155.	1.4	7
281	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451.	3.2	13
282	Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1082-1090.	2.1	12
283	Solid tumours hijack the histone variant network. <i>Nature Reviews Cancer</i> , 2021, 21, 257-275.	12.8	39
284	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. <i>Diagnostics</i> , 2021, 11, 481.	1.3	5
285	Advanced Pediatric Diffuse Pontine Glioma Murine Models Pave the Way towards Precision Medicine. <i>Cancers</i> , 2021, 13, 1114.	1.7	8
286	Imaging of brain tumors in children: the basics—a narrative review. <i>Translational Pediatrics</i> , 2021, 10, 1138-1168.	0.5	5
287	Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of <sup>11</sup> C-Labeled ALK2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 846-850.	1.3	5
289	Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 38, 127858.	1.0	5
290	Pathogenic ACVR1 <sup>R206H</sup> activation by Activin A-induced receptor clustering and autophosphorylation. <i>EMBO Journal</i> , 2021, 40, e106317.	3.5	24
291	Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders. <i>Biomedicines</i> , 2021, 9, 736.	1.4	7
293	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	5.8	27
294	Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis. <i>Genes</i> , 2021, 12, 1187.	1.0	9

#	ARTICLE	IF	CITATIONS
295	MiR-130a Acts as a Tumor Suppressor MicroRNA in Cutaneous Squamous Cell Carcinoma and Regulates the Activity of the BMP/SMAD Pathway by Suppressing ACVR1. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1922-1931.	0.3	13
296	Recent Advances in ALK2 Inhibitors. <i>ACS Omega</i> , 2021, 6, 20729-20734.	1.6	14
297	Reverting to single-cell biology: The predictions of the atavism theory of cancer. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 49-55.	1.4	12
298	Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i> -Mutant Diffuse Intrinsic Pontine Glioma. <i>Cancer Discovery</i> , 2022, 12, 416-431.	7.7	25
299	Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas. <i>Frontiers in Genetics</i> , 2021, 12, 742561.	1.1	15
300	Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab137.	0.4	2
301	Brainstem Tumors. , 2019, , 1-35.		4
302	Epigenetics in Health and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1253, 3-55.	0.8	317
303	Fostering open collaboration in drug development for paediatric brain tumours. <i>Biochemical Society Transactions</i> , 2019, 47, 1471-1479.	1.6	3
304	Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better. <i>Neuro-Oncology</i> , 2017, 19, 1017-1018.	0.6	3
305	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. <i>Neurosurgery</i> , 2020, 87, E680-E688.	0.6	11
308	Pediatric Brain Tumors. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 1727-1757.	0.4	19
309	Histone modifications and a choice of variant: a language that helps the genome express itself. <i>F1000prime Reports</i> , 2014, 6, 76.	5.9	42
310	Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes. <i>PLoS Genetics</i> , 2016, 12, e1006081.	1.5	14
311	A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic Agent. <i>PLoS ONE</i> , 2015, 10, e0118926.	1.1	57
312	Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. <i>PLoS ONE</i> , 2017, 12, e0176855.	1.1	21
313	Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. <i>Oncotarget</i> , 2016, 7, 65696-65706.	0.8	55
314	New <i>in vivo</i> avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. <i>Oncotarget</i> , 2017, 8, 52543-52559.	0.8	41

#	ARTICLE	IF	CITATIONS
315	BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. <i>Oncotarget</i> , 2017, 8, 62962-62975.	0.8	46
316	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. <i>Oncotarget</i> , 2018, 9, 5233-5250.	0.8	12
317	Chromatin remodeling defects in pediatric brain tumors. <i>Annals of Translational Medicine</i> , 2018, 6, 248-248.	0.7	9
318	Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. <i>Current Neuropharmacology</i> , 2017, 15, 88-97.	1.4	88
319	Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas. <i>Current Neuropharmacology</i> , 2016, 15, 98-103.	1.4	12
320	Diffuse midline glioma, H3-K27M mutant: Awareness leads to identification. <i>Glioma (Mumbai, India)</i> , 2019, 2, 55.	0.0	1
321	Polycomb group proteins in cancer: multifaceted functions and strategies for modulation. <i>NAR Cancer</i> , 2021, 3, zcab039.	1.6	10
323	Imágenes para la predicación del Evangelio. Presencia de las Imprese sacre del obispo Aresi en la oratoria sagrada espa±ola de la Edad Moderna. <i>Hispania Sacra</i> , 2016, 68, 659.	0.1	0
329	Brainstem Tumors. , 2020, , 1957-1983.		0
331	Recent perspectives of molecular aberrations in pediatric high-grade glioma. <i>Minerva Pediatrica</i> , 2020, 72, 116-122.	2.6	0
332	Radiation and Chemotherapy for Brainstem Tumors. , 2020, , 321-345.		0
333	Immune-stimulatory (TK/Ft3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas. <i>Oncotarget</i> , 2020, 11, 4607-4612.	0.8	7
335	A Protocol for the Generation of Treatment-naïve Biopsyderived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models. , 2020, 1, 158-167.		3
336	Diffuse Midline Glioma“ Diffuse Intrinsic Pontine Glioma. , 2020, , 159-193.		2
337	Future Therapies for Malignant Brainstem Tumors. , 2020, , 347-392.		0
338	TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. <i>Acta Neuropathologica Communications</i> , 2021, 9, 178.	2.4	8
339	Histone H3K27M Mutation in Brain Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1283, 43-52.	0.8	10
340	Histone Lysine-to-Methionine Mutation as Anticancer Drug Target. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1283, 85-96.	0.8	1

#	ARTICLE	IF	CITATIONS
341	EZH1P: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 143, 1-13.	3.9	17
342	Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. <i>Oncogene</i> , 2022, 41, 461-475.	2.6	39
343	H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. <i>Journal of Neuro-Oncology</i> , 2021, 155, 225-234.	1.4	20
344	Label-free identification of human glioma xenograft of mouse brain with quantitative ultraviolet photoacoustic histology imaging. <i>Journal of Biophotonics</i> , 2022, 15, e202100329.	1.1	5
345	Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape. <i>Cancers</i> , 2021, 13, 6251.	1.7	12
346	Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. <i>Neuro-Oncology</i> , 2022, 24, 1352-1363.	0.6	29
347	Oncohistones: Hijacking the Histone Code. <i>Annual Review of Cancer Biology</i> , 2022, 6, 293-312.	2.3	8
348	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	5.8	22
349	The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review. <i>Glioma (Mumbai, India)</i> , 2022, 5, 5.	0.0	0
350	Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas. <i>Frontiers in Oncology</i> , 2022, 12, 858148.	1.3	9
351	The molecular characteristics of low-grade and high-grade areas in desmoplastic infantile astrocytoma/ganglioglioma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	5
352	The epigenetic—metabolic interplay in gliomagenesis. <i>Open Biology</i> , 2022, 12, 210350.	1.5	2
353	Childhood Malignant Brain Tumors: Balancing the Bench and Bedside. <i>Cancers</i> , 2021, 13, 6099.	1.7	15
354	Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response. <i>Nature Communications</i> , 2021, 12, 7216.	5.8	19
355	Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors — An update. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114303.	6.6	21
356	An ACVR1 activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans. <i>Pain</i> , 2022, Publish Ahead of Print, .	2.0	3
360	Risk stratification of H3 K27M—mutant diffuse midline gliomas based on anatomical locations: an integrated systematic review of individual participant data. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 30, 99-106.	0.8	5
361	Functionalized Macrophage Exosomes with Panobinostat and PPM1D—siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. <i>Advanced Science</i> , 2022, 9, e2200353.	5.6	29

#	ARTICLE	IF	CITATIONS
362	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	3.9	7
363	Duality of bone morphogenetic proteins in cancer: A comprehensive analysis. <i>Journal of Cellular Physiology</i> , 2022, 237, 3127-3163.	2.0	7
364	Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	22
365	The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	12
366	Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	3
367	The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential. <i>BMC Biology</i> , 2022, 20, .	1.7	10
368	The Intricate Epigenetic and Transcriptional Alterations in Pediatric High-Grade Gliomas: Targeting the Crosstalk as the Oncogenic Achillesâ€™ Heel. <i>Biomedicines</i> , 2022, 10, 1311.	1.4	3
370	Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 390-414.	1.0	9
371	Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1159-1164.	1.3	3
372	Use of Imaging Mass Cytometry in Studies of the Tissue Microenvironment. , 2022, , 345-364.		1
373	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. <i>Nature Cancer</i> , 2022, 3, 994-1011.	5.7	20
374	Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. <i>Clinical Cancer Research</i> , 2022, 28, 3965-3978.	3.2	24
375	A systematic review of the clinicopathological features and prognostic outcomes of DICER1-mutant malignant brain neoplasms. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 30, 308-315.	0.8	3
376	Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5. <i>Nature Cancer</i> , 2022, 3, 1105-1122.	5.7	14
377	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. <i>Pharmaceutics</i> , 2022, 14, 1762.	2.0	4
378	Activation of AcvR1-Mediated Signaling Results in Semilunar Valve Defects. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 272.	0.8	0
379	Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting. <i>Briefings in Functional Genomics</i> , 2023, 22, 123-142.	1.3	0
380	Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211136.	1.4	8

#	ARTICLE	IF	CITATIONS
381	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genomics, 2022, 2, 100179.	3.0	74
382	Modeling Brain Tumors Using Genetically Edited Brain Organoids. Neuromethods, 2023, , 159-171.	0.2	0
383	Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nature Communications, 2022, 13, .	5.8	13
385	Investigating pathological epigenetic aberrations by epi-proteomics. Clinical Epigenetics, 2022, 14, .	1.8	2
386	K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nature Genetics, 2022, 54, 1865-1880.	9.4	27
387	Defining the cell of origin for diffuse midline gliomas. Nature Genetics, 2022, 54, 1770-1771.	9.4	1
388	Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry. Frontiers in Oncology, 0, 12, .	1.3	5
389	Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type. Frontiers in Oncology, 0, 12, .	1.3	9
390	Midline brain hamartomatous lesions in fibrodysplasia ossificans progressiva with <i>ACVR1</i> mutations. Neuropathology, 0, , .	0.7	0
391	Chromatin mutations in pediatric high grade gliomas. Frontiers in Oncology, 0, 12, .	1.3	1
392	Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. Journal of Medicinal Chemistry, 2023, 66, 2143-2160.	2.9	11
393	Diffuse intrinsic pontine glioma: Insights into oncogenesis and opportunities for targeted therapy. Pediatric Hematology Oncology Journal, 2023, 8, 73-79.	0.1	2
394	Synapse-tuned CARs enhance immune cell anti-tumor activity. Nature Biotechnology, 2023, 41, 1434-1445.	9.4	12
395	Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research. Biomedicines, 2023, 11, 527.	1.4	2
396	Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. Scientific Reports, 2023, 13, .	1.6	1
403	Malignant Glioma. Advances in Experimental Medicine and Biology, 2023, , 1-30.	0.8	8